HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

Phase 2 Completed 24 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) · collab Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well HIF-2 alpha inhibitor PT2385 works in treating patients with recurrent glioblastoma. HIF-2 alpha inhibitor PT2385 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2017-09-14
Primary completion: 2019-08-31
Completion: 2020-06-05

Outcome

Missed primary endpoint

paper No objective radiographic responses were observed; PMID 37864646 ↗

Publications

Strowd R, Ellingson B, Raymond C, Yao J, Wen PY, Ahluwalia M, Piotrowski A, Desai A, Clarke JL, Lieberman FS, Desideri S, Nabors LB, Ye X, Grossman S. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. J Neurooncol. 2023 Oct;165(1):101-112. doi: 10.1007/s11060-023-04456-7. Epub 2023 Oct 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PT2385	Small molecule	800 mg	Oral